Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xiangjurupining Capsule for Hyperplasia of Mammary Glands
NCT06685978Phase 3Recruiting
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Xiangjurupining Capsule placebo in hyperplasia of mammary glands (2 arms), sponsored by Tasly Pharmaceutical Group Co., Ltd. Primary endpoint: Pain relief rate. Started Apr 2024; status: recruiting.
02
Drugs
Xiangjurupining Capsule placebo
03
Conditions
hyperplasia of mammary glands
Beyond the preview
Go deeper on NCT06685978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06685978.